A Phase 2, Double-blind, Placebo-controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects with Relapsing-remitting Multiple Sclerosis.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Ustekinumab
Interleukin-12 inhibitor|Interleukin-23 inhibitor
What it measured
Main measures
The cumulative number of new Gd-enhancing T1-weighted lesions on cranial MRIs through week 23.
MRI lesions
Who could take part
Relapsing MS
Inclusion: 1. Be >/= 18 and </= 65 years of age at screening. Exclusion: 1. Have a CNS disease (eg, CNS lymphoma, systemic lupus erythematous) that could
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective of this study is to assess the dose-response effect of multiple subcutaneous (SC) injections of CNTO 1275 in subjects with RRMS based on the cumulative number of new gadolinium (Gd)-enhancing T1-weighted lesions on cranial MRIs through week 23.
Loading reviews and guidelines…
Related trials
- LTS18002
Phase 3 · Not yet recruiting
Still running
- FREXALT
Phase 3 · Running, not recruiting
Still running
- LITMUS
Not a drug-phase study · Completed (inferred)
Results posted, no main test reported
- Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with RMS
Phase 2 · Stopped early
Stopped early
- SUSTAIN
Phase 3 · Stopped early
Stopped early
- ZEUS
Not a drug-phase study · Stopped
Stopped early
History
Started
Sept 2004
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error